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Abstract: Angiogenesis inhibitors offer a promising new treatment modality in oncology. Ho-
wever, the optimal administration regimen is often not well-established, despite the fact that
it might have substantial impact on the outcome. The aim of the present study was to in-
vestigate this issue. Eight weeks old male C57Bl/6 mice were implanted with C38 colon
adenocarcinoma, and were given either daily (n = 9) or single (n = 5) dose of bevacizumab.
Outcome was measured by tracking tumor volume; both caliper and magnetic resonance
imaging was employed. Longitudinal growth curves were modelled with mixed-effects mo-
dels (with correction for autocorrelation and heteroscedasticity, where necessary) to infer
on population-level. Several different growth models (exponential, logistic, Gompertz) were
applied and compared. Results show that the estimation of the exponential model is very reli-
able, but it prevents extrapolation in time. Nevertheless, it clearly established the advantage
of the continuous regime.
Keywords: mixed effects models; tumor growth; angiogenesis inhibition; dosing regimen
1 Introduction
Biomedical experiments aim to investigate and understand physiological and pat-
hophysiological processes. There are three main types of the biomedical experi-
ments: in vivo, in vitro and in silico experiments. In vivo studies use living or-
ganisms for the experiment, these are animal studies and clinical trials. In vitro
studies examine biological processes in a controlled environment but outside of a
living organism. Finally, in silico studies are performed on computer or via compu-
ter simulation. It is clear that in vivo experiments describes most precisely the real
processes and as a result, we can observe the overall effects of an experiment on a
living organism. The drawback, however, is the use and sacrifice of animals (in case
of animal experiments), and according to the principles of the 3Rs (replacement,
reduction and refinement) [1] we should avoid or replace the use of animals (re-
placement), and minimize the number of animals used per experiment (reduction).
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In our experiment, we used 14 mice in total (in order to fulfill the principle of re-
duction), nevertheless the obtained results are satisfactory to carry out statistical
modelling (which is a replacement method since in the future these models can be
used for further investigation instead of the use of mice).
In cancer treatment, a novel approach is identifying cancer-specific mechanisms
and develop therapies based on these key points or targets. These targeted mole-
cular therapies [2] contain several different specific treatment types. Knowing that
angiogenesis (namely the formation of new blood vessels) has a key role in tumor
growth, inhibiting angiogenesis could lead to slowed tumor growth or, in particular,
it can cease the whole growth process [3]. Hahnfeldt et al [4] carried out a tumor
growth model which describes the growth process under antiangiogenic therapy;
however, the biological fundamentals of this model have become outdated.
In particular, the aim of our study was to determine whether the continuous adminis-
tration of an antiangiogenic inhibitor offers advantages over the more conservative
(higher dose – less frequent administration) approach.
1.1 Tumor Growth Models
While tumor growth involves many complicated biological mechanisms, its overall
nature – in terms of weight, size or volume – often follows surprisingly simple
patterns. This was recognized decades ago (especially following the landmark paper
of Laird in 1964 [5]) and has been utilized – in spite of their limitations – ever since
both to understand the biological foundations and to provide modelling, for instance
in preclinical studies of drug candidates using xenograft tumors implanted in test
animals.
These models might be purely empirical, like the Gompertzian growth discussed
by Laird, or they might involve considerations about the underlying biological me-
chanisms (mechanistic and semi-mechanistic models), like the exponential-linear
model by Simeoni [6].
Empirical models will be used in the present study. While some models (e.g. [7])
directly incorporate the effect of drugs (making them at least semi-mechanistic),
now the same – empirical – growth model is assumed to apply in both the control
and the treated groups; the drug exerts its effects by altering the parameters of the
curve.
1.1.1 Exponential Growth (Inital Phase, No Plateau)
One of the earliest observations about tumor growth modeling was that in many ca-
ses, the growth – both in vivo and in vitro – exhibits exponential nature in its earliest
period. Biologically, it correspends to the phase where the resource-limitation is not
apparent, and in that sense the tumor can ”freely” grow, limited only by its own size
which defines the pool of cells that can divide.
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The growth thus obeys the following ordinary differential equation (DE):
dV (t)
dt = aV (t); (1)
the solution of which is the well-known exponential growth formula:
V (t) =V0eat , (2)
where V (t) is the tumor volume (or any dimension of the tumor, in the general case),
with V0 =V (0).
In almost every practical case, this model can only describe the early phase of tumor
growth. In particular, it always leads to an infinite growth, the reason being that the
effect of the appearence of growth-limiting factors is not accounted for.
As measurements in the present study were made in such initial period, apparently
even the exponential growth provides adequate fit. However, these models are still
problematic, even in this case, simply because they offer no possibility to extrapolate
in time. Even if the plateau is not yet apparent, we might try to model it (or it might
be an especially important task in such case) using only pre-plateau information –
this is not possible with the exponential model.
1.1.2 Sigmoid Growth (Plateau Accounted For)
The typical solution to this problem is the application of sigmoid-like growth cur-
ves. Such models can capture the asymptotical phase, and thus the plateau can be
estimated – even from data collected before reaching the plateau. The question will
be, of course, the reliability if the observations are far from the plateau-phase.
We will use two popular sigmoid models in the present study, for a review of the
alternatives, see [8, 9, 10].
Note that many such model is a special case of the DE
dV (t)
dt = aV (t)
α −bV (t)β , (3)
which is usually called the generalized two-parameter model, with appropriate choice
of the a, α , b, β parameters. (As a matter of fact, even the exponential model is a
special case with a = 1, α = 1, b = 0.)
Gompertz growth One of the earliest such model (used already by Laird in 1964 [5]),
and perhaps the most widely used even today, is the Gompertz growth. It is governed
by the following DE:
dV (t)
dt = aV (t)−bV (t) lnV (t) , (4)
giving rise to the Gompertz growth curve:
V (t) = e
a
b−( ab−lnV0)e−bt . (5)
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(This is also the limiting case of Equation 3 when appropriate definitions are used [11].)
In the current study, the following – equivalent – parametrization will be used:
V (t) = Ae−b2·b
t
3 , (6)
where A represent the asymptote (level of the plateau), while b2 and b3 determine
the transition.
One well-known property of Gompertz growth is that the derivative at the initial
rising period is higher than at the period before reaching the asymptote, i.e. the two
transitions are not symmetric.
Logistic growth The logistic growth is another well-known sigmoid model; as
opposed to the Gompertz curve, it is symmetric in both transitions.
It obeys the following DE:
dV (t)
dt = aV (t)−bV (t)2 (7)
giving rise to the logistic growth curve:
V (t) =
a/b
1− (1− abV0 )e−at
. (8)
(This is also a special case of Equation 3 with α = 1 and β = 2.)
In the present study, the following – equivalent – parametrization will be used:
V (t) =
A
1+ e
tm−t
s
, (9)
where A represent the asymptote (level of the plateau), tm is the mid-point (time to
reach half of the plateau level), and s determines the steepness of the growth.
2 Material and Methods
2.1 Experimental Setting
2.1.1 Mouse and Tumor Type
Fourteen eight weeks old male C57Bl/6 mice were implanted with C38 colon ade-
nocarcinoma. A piece of tumor was transplanted subcutaneously in the recipient
animal on the 1st day of the experiment.
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2.1.2 Treatment
We investigated the effect of bevacizumab which is an angiogenic inhibitor [12].
Two groups were created to compare the effectiveness of the prescribed, one large
dose protocol and a daily, quasi-continuous treatment. The control group contained
5 mice, each one received 200 µg bevacizumab dose intraperitoneally on the -1st
day and on the 17th day of the experiment (this bolus was designed for an 18-
day treatment). By contrast, mice in the case group (9 mice) received 1.11 µg
bevacizumab intraperitoneally every day from the -1st day until the last day of the
experiment (the total period was 20 days); that is to say, one-tenth dose of control
dose spread over 18 days.
The above dosage was selected based on the fact that the recommended administra-
tion of bevacizumab is 5−10 mg/kg dose for 2-3 weeks [13]. We have administered
10 mg/kg body weight intraperitoneally, which means 200 µg bevacizumab per a
mouse, since the mass of the mice in the experiment was approximately 20 g.
2.1.3 Tumor Volume Measurement
Tumor volume was measured with digital caliper and small animal MRI as well.
Due to the subcutaneous localization, two dimensions of the tumor can be measu-
red with digital caliper. The third dimension should be estimated, and assuming a
certain shape, tumor volume can be approximated. Based on different estimation
methods, we obtained three different tumor volume values for each measurement
point [14]. Measurements with caliper were made on the 0th, 2nd, 4th, 6th, 8th,
10th, 12th, 14th, 16th, 18th and 19th days of the experiment.
In order to verify our estimation methods based on caliper measurements, we used
small animal MRI for tumor volume determination as well, since MRI provides
much more precise volume measurement. Measurements with small animal MRI
were carried out on the 0th, 4th, 7th, 11th, 14th and 19th days of the experiment.
Figure 1 shows tumor volumes using all the estimation methods.
Mice were sacrificed at the end of the treatment, in strong accordance with the 3Rs
principles.
2.2 Statistical Tools
First, individual curves were fitted for each test animal (using each measurement
method) with all three models. Fitting was performed with nonlinear least squares
(NLS) [15, 16]. Gauss-Newton algorithm turned out to be incapable of converging
in every case (sigmoid growth curves were problematic, when even the end of the
observed data was far from reaching the plateau). Thus, Levenberg-Marquardt al-
gorithm [17] was employed, which successfully converged for all three models for
every growth curve.
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Figure 1
Measured tumor volumes (with all measurement methods).
This approach provides the best fit as it estimates individual parameters for all sub-
ject and measurement method, but this is also the very reason that prevents generali-
zation: we have separate models, thus it is not possible to infer on a higher level (i.e.
the population of parameters). As we are now primarily interested not in these par-
ticular subjects, but rather on the population from which they are coming, a model
will be used which explicitly incorporates this aspect: the mixed effects model [18,
19].
These models assume that parameters are not fixed values, but rather realizations of
a random variable, most typically normal random variate; this is called a random
effect. These are characterized by mean and variance (and possibly covariance for
different such distributions). Therefore the estimation focuses not on the individual
parameters, but rather on these parameters of the population.
To formalize: denoting the tumor volume of the ith subject at measurement number
j with Vi j we have
Vi j = f (φ i j, ti j)+ εi j, εi j ∼N (0,σ2), (10)
where f represents the nonlinear functional form – in the present study, exponential,
Gompertz or logistic – of time (ti j being the time when the jthe measurement was
made on the ith subject) determined the parameters φ i j, the dimensionality of which
corresponds to the number of parameters in the growth curve (2 or 3 in our cases).
Now we assume that these parameters depend on whether the test animal belongs to
the treated or to the control group and on the measurement method, that is
φ i j = (β 0 +bi)+β GroupGroupi +βMeasMethMeasMethi, (11)
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where random effects bi ∼N (0,ψ ) and β s are vectors containing the fixed effects
for each parameter of the growth curve. (In this case φ i j only depends on i, in other
words, we had no time-varying covariates.) For instance, exponential growth curve,
using the more usual notation, is modelled as
Vi(t) =
(
V0 +bV0,i +β
(V0)
GroupGroupi +β
(V0)
MeasMethMeasMethi
)
·
· e
(
a+ba,i+β
(a)
GroupGroupi+β
(a)
MeasMethMeasMethi
)
t
+ εi,t .
(12)
We assumed that ψ is diagonal, i.e. the random effects are uncorrelated. Resi-
dual (within-group) error εi j is assumed to be independent and independent from all
random effects too.
To sum up, we assume that these covariates act by altering the parameters of the –
same – functional form. In particular, this means that the effect of drug is incorpo-
rated by assuming that the tumor growth obeys the same law under treatment, but
with different parameters.
This model assumes, among others, that
• the variance of the error terms is a constant (i.e. no heteroscedasticity pre-
sent),
• the error terms are uncorrelated (i.e. no residual autocorrelation present).
These assumptions were checked by plotting the standardized residuals versus the
time – the only covariate in the models – and the autocorrelation function of the resi-
duals, respectively. In case of violation, appropriate weighting functions and within-
subject autocorrelation functions – with autoregressive, moving average (ARMA)
models – were included in the models [18]. Models were characterized with Akaike’s
Information Criterion (AIC), among others.
This analysis updates a previous one [20] with more elaborate individual curve fit-
ting and a more rigorous mixed-effects modelling.
2.3 Programs Used
R statistical program package [21] (version 3.3.2) was used with libraries min-
pack.lm [22] (version 1.2-0) and nlme [23] (version 3.1-128) to carry out the cal-
culations using a custom script developed for this purpose that is available at the
corresponding author on request. Visualizations were created with the lattice li-
brary [24] (version 0.20-34).
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Figure 2
Point estimates with 95% confidence intervals for the parameters of the individual exponential model
(for each animal using each measurement method).
3 Results
3.1 Individual Fitting
Results obtained with the exponential model are shown – for each subject and mea-
surement method – on Figure 2.
a parameters are rather homogeneous, but V0 shows substantial heterogeneity (with
a clear tendency of MRI measurements being higher than any of the caliper measu-
rements).
The fitting of sigmoid models is much more complicated. Figure 3 shows that the
parameteres associated with the plateau can be estimated only with extreme uncer-
tainty in certain cases. (Note the logarithmic scale of the Figure.) The reason is
that the data gives information only on the early phase of the growth, far from the
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plateau, which makes extrapolation very hard.
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Figure 3
Point estimates with 95% confidence intervals for the parameters of the individual sigmoid models (for
each animal using each measurement method). Note the logarithmic scale for certain parameters.
3.2 Population-level Mixed Model
3.2.1 Exponential Growth
Residuals of the exponential model showed no substantial dependence on time, but
were definitely heteroskedastic in terms of measurement method (Figure 4), so dif-
ferent variances were assumed for each measurement method.
The autocorrelation function (Figure 5) showed significant residual autocorrelation.
As it was not disappearing even at higher lags, it was assumed to be basically MA-
process; finally ARMA(1,4) specification turned out to be practically removing re-
sidual autocorrelation.
In this – now diagnostically correct – model, the standard deviation of the random
effect for the V0 was 13.14565, for the a it was 0.02614131. The residual standard
deviation and AIC is shown in Table 1.
Table 1
Residual standard deviations and AICs of different population-level models
Model Residual standard deviation AIC
Exponential 113.2 6474
Logistic 86.6 6602
Gompertz 660 8677
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Figure 4
Residuals of the exponential model plotted as a function of day, by measurement method.
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Figure 5
Autocorrelation function of the residuals from the exponential model, with critical values at 5%
significance level.
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Figure 6
Predicted growth (on population-level) of the tumor volume for Days 0 to 150. Different colors indicate
different measurement methods (see legend), solid line indicates control group, while dashed line
indicates treated group.
In this model, the intercept of V0 is 40.5 with MRI measurement having significantly
higher values than caliper measurements (+275.2 compared to Caliper-1). The in-
tercept of a is 0.18349, but now MRI measurements are having significantly lower a
(−0.04342 compared to Caliper-1), Caliper-2 however exhibits significantly higher
a (+0.02894).
The treatment’s effect is very interesting: it does slightly significantly alter V0
(−18.05230, p = 0.0354), but it does have a more significant effect on a, being
associated with −0.03746 change (p = 0.0197). I.e. the continuous regimen decre-
ases the rate of growth – which shows the benefit of this dosing regimen.
3.2.2 Sigmoid Growth
Sigmoid growth models were barely approximable (as already expected from the
results of the individual fitting), so no attempt was made to include special variance
or autocorrelation function.
The results of the mixed models are shown (Figure 6) as – population-level – pre-
dicted tumor volumes for Days 0 to 150 (for each measurement type and for the
treated/control groups). Note that the original data spanned from Days 0 to 19, so
this exemplifies the extrapolation with the models.
The residual standard deviations and AICs are shown in Table 1.
The effect of treatment was significant for the mid-point parameter of the logistic
growth (p = 0.0228), but it was not significant for any parameter of the Gompertz
growth. In particular, the asymptotic levels were substantially lower in both cases
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(−5136 with the intercept being 12071 for the logistic model, −64657 with the
intercept being 100263 for the Gompertzian model), but these were insignificant,
as they were very hard to estimate, as expected (also note the extreme difference
between the two models in asymptotic levels).
The asymptotic level in the logistic model was significantly – and substantially –
higher with MRI (+10841, p < 0.001).
4 Discussion
It was possible to reliably estimate all parameters of the exponential growth model,
indicated by the consistent and rather narrow confidence intervals in the individual
fits and the acceptable residual standard deviation in the mixed model. The results
show the effect of the treatment; already demonstrated in an earlier research [25].
In contrast, the estimates for the sigmoid-growth models were exceedingly variable
evidenced by the very wide confidence intervals. The population level model exhi-
bited extremely poor fit, with enormously high residual deviations. Nevertheless, it
could concluded that the logistic modell still provided better fit than the Gompert-
zian.
In short, it was not possible to reliably estimate these models, the reason being the
rather short observation period that was available, showing only the very early pe-
riod of tumor growth. Notwithstanding, results point out the possibility to estimate
the plateu phase, which is a very interesting and promosing parameter – in additi-
onal to the initial rate of growth, already captured by the exponential model –, but
trusthworthy estimation of this requires more observation.
Results also highlight the differences between the measurement devices, clearly sho-
wing that measurements made with MRI are systematically higher than any of the
caliper measurements.
One strength of our approach was that it integrates all factors (treatment and mea-
surement device) into one single model, allowing us to investigate both the effect
of the treatment and the effect of the applied measuring method at the same time.
Also, the mixed effects approach allows a smooth and elegant usage of the indivi-
dual measurements to create a population-level model. In addition to that, we have
the possibility to test several potentional functional forms; with some of them, we
are also able to extrapolate in time, and capture clinically relevant parameters.
The most important limitation was the rather small number of test subjects, and the
too short observation period to estimates some of the models.
Conclusion
The exponential model could be estimated in a robust manner, both individually,
and in the population-level with the mixed effects model. Results confirm the effect
of the treatment, and make it possible to quantify this.
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In contrast, the sigmoid-like growth curves were almost impossible to estimate, re-
vealing the limitations of our data. Nevertheless, the possibility to estimate such
models – making extrapolation possible – presents a promising opportunity.
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